(Q34941330)

5 August 2017

1 reference

title

Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations (English)

1 reference

5 August 2017

0 references

1

Freudenreich O

1 reference

5 August 2017

Goff DC

2

1 reference

PubMed ID

12366465

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

Acta Psychiatrica Scandinavica

5 August 2017

1 reference

5 August 2017

106

1 reference

5 August 2017

5

1 reference

5 August 2017

323-330

1 reference

Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders.

5 August 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

New Insights into the Biology of Schizophrenia through the Mechanism of Action of Clozapine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Clozapine augmentation: safety and efficacy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Clozapine in China: a review and preview of US/PRC collaboration

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Addition of risperidone to clozapine therapy in chronically psychotic inpatients.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

An open trial of risperidone augmentation of partial response to clozapine.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Risperidone and clozapine combination for the treatment of refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Risperidone added to clozapine: impact on serum prolactin levels.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Atrial ectopics with clozapine-risperidone combination

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Hoarding and clozapine-risperidone combination

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Agranulocytosis after addition of risperidone to clozapine treatment

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Interaction between olanzapine and haloperidol

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Cross-tapering clozapine and risperidone

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Pharmacokinetic interaction between risperidone and clozapine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

The Mechanism of Action of Novel Antipsychotic Drugs

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Limitations of controlled augmentation trials in schizophrenia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Thinking small: research designs appropriate for clinical practice

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Determining optimal therapy--randomized trials in individual patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Staging: a neglected dimension in psychiatric classification

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

The long-term course of the schizophrenic psychoses

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Defining treatment refractoriness in schizophrenia.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

Evaluation of treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

A separate disease within the syndrome of schizophrenia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.01331.X

7 January 2021

10.1034/J.1600-0447.2002.01331.X

Identifiers

DOI

1 reference

release_fn6lqdcwwjgfjgq77sjqh7trii

5 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fn6lqdcwwjgfjgq77sjqh7trii

24 November 2022

mapped directly with Wikidata item

PubMed ID

12366465

1 reference

PubMed ID

12366465